
Long-acting cabotegravir plus rilpivirine (Cabenuva) achieved superior viral suppression vs daily oral antiretroviral therapy at 6months in treatment-experienced people with HIV and detectable viremia in the phase 3b CROWN trial.
Jessica Justman, MD, shares why the Population-based HIV Impact Assessment Project is so important.
Jessica Justman, MD, senior technical director, ICAP, Mailman School of Public Health & associate professor of medicine in epidemiology, Columbia University, shares that the
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Subscribe






